PSILOCINMEDS.COM

WELCOME TO PSILOCINMEDS.COM

PSILOCINMEDS.COM is plural catalog English: Psilocin Meds—formulary pages and education hubs that already say “psilocin meds” when they mean multi-SKU or pathway catalogs, not singular PsilocinMed clinic tone.

Best-fit buyers: education publishers; clinic networks; investor decks; defensive holders. Exact-fit launch: a Psilocin Meds catalog hub with pathway tiles, safety FAQ, and waitlist CTA.

The same COMP005 Phase 3 result—−3.6 MADRS at week 6 vs placebo (p<0.001)—is the clinical proof-point buyers already model against medical-psychedelic catalogs.^[1] Part A’s 258 dosed participants across 32 U.S. sites show the multi-site operational reality behind plural “meds” framing.^[2] That pivotal spine frames why exact Psilocin Meds inventory matters—not an invented category TAM.

Why Choose PSILOCINMEDS.COM

• 📚 Psilocin Meds lockup: Plural catalog English already spoken.
• 📉 Phase 3 signal: COMP005 −3.6 MADRS week 6.^[1]
• 🏥 Multi-site reality: 258 participants / 32 U.S. sites.^[2]
• 🔍 Vs PsilocinMed: Plural Meds ≠ singular Med clinic door.
• 📋 Formulary fit: Built for multi-pathway education pages.
• ✨ Catalog clarity: Sounds like a SKU/pathway index, not one drug name.

BUY NOW - $19,318

Buy Now — PSILOCINMEDS.COM. Own the Psilocin Meds hostname.

Purchase PSILOCINMEDS.COM today through our trusted partners:

• GoDaddy
• Xela Domains
• Afternic

WHAT DOES ALINA IWANSON THINK?

"PsilocinMeds.com is plural catalog inventory—Meds, not singular Med."

Alina Iwanson, Auction Specialist
Contact Alina Iwanson via Email

Related Domains

FAQs

Who buys PsilocinMeds.com?

Education publishers, clinic networks, IR desks, and defensive holders.

What figures are cited?

Compass COMP005 −3.6 MADRS; 258 participants / 32 U.S. sites.

Vs PsilocinMed.com?

Plural catalog vs singular Med—unique siblings.

Can this sell controlled substances?

No—name only; buyer owns every license and advertising rule.

Contact Us

Feel free to reach out to explore the potentials of PSILOCINMEDS.COM for your business. 📬

📧 Email: info@xeladomains.com
📞 Phone: (858) 429-9352

Social Networks

Follow our journey and connect with us on Instagram and LinkedIn for updates and more information.

Instagram | LinkedIn

REFERENCES

1. Compass Pathways — COMP005 Phase 3: COMP360 25 mg vs placebo −3.6 MADRS at week 6 (p<0.001); FDA Breakthrough Therapy for TRD
2. Compass Pathways — COMP005 Part A: 258 participants dosed across 32 U.S. sites (synthesized psilocybin TRD pivotal)